Disclosure

Geneva, November 1, 2007. On October 30, 2007, the Board of Directors of Unilabs SA (SWX: ULB) was informed by the legal representative of the former shareholders' group consisting of Trident European Fund, Grand Cayman, Selectium Opportunities Fund, Grand Cayman, Selectium Europe Fund, Grand Cayman, Susqehanna Ireland Ltd., Dublin, and GoldenPeaks Capital Partners AG, Zug, of the dissolution of the shareholders' group, which had been notified to the company on September 5, 2007. The Board of Directors acknowledges today's announcement of the shareholders' group to withdraw their request for an extraordinary general meeting and a separate meeting of the holders of bearer shares. About Unilabs The Unilabs Group (SWX: ULB) is the European leader of clinical testing laboratories. With over 50 laboratories and over 1800 employees operating in 6 countries, Unilabs tests over 3.5 million samples per year using more than 1500 different tests. Unilabs' clinical testing services are used by over 60 public and private hospitals in France, Spain and Switzerland. Unilabs has been listed on the SWX Swiss Stock Exchange since 1997. For further information, please contact Christophe Lamps, (tel. +4122718 37 46 or +4179 476 26 87; mail: clamps@rochat-pr.ch). Our press releases are also available on the Internet at our website www.unilabs.com. --- End of Message --- Unilabs SA C.P. 2559 Genève 1 WKN: 906648; ISIN: CH0012561640; Index: SPI, SSCI, SBIOM, SLIFE, SPIEX; Listed: Main Market in SWX Swiss Exchange;